Chardan

Assembly Biosciences Inc (NASDAQ: ASMB) made a poster presentation of interim results from two early-stage studies for its ABI-H073, a hepatitis B virus core protein allosteric modulator, at the EASL International Liver Congress 2018 in Paris. The Analyst Chardan analyst Gbola Amusa...

Regenxbio Inc (NASDAQ: RGNX) rode a tailwind Monday from the announced acquisition of its partner AveXis Inc (NASDAQ: AVXS), and the benefits may keep coming. The Rating Chardan analyst Gbola Amusa reiterated a Buy rating on Regenxbio and increased the price target from $85 to $90. The...

AveXis Inc (NASDAQ: AVXS) announced Monday its sale to Novartis AG (ADR) (NYSE: NVS) for $8.7 billion, or $218 per share. The deal didn’t come as a complete surprise. The Rating Chardan analyst Gbola Amusa maintained a Buy rating on AveXis and increased the price target from $140 to $218...

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) could become a player in the emerging field of small RNA interference, or RNAi, according to Chardan Capital Markets.  The Analyst Chardan analyst Keay Nakae started coverage of Dicerna with a Neutral rating and no price target...

Novavax, Inc. (NASDAQ: NVAX) popped 31 percent Wednesday evening after management announced the NanoFlu Vaccine demonstrated improved immune responses over alternative flu vaccines. Biotech experts disputed the data’s significance, with STAT News' Adam Feuerstein confessing skepticism. I...

Catalyst Biosciences Inc (NASDAQ: CBIO), a nano-cap clinical-stage biopharmaceutical company that focuses on the treatment of hemophilia, has high expectations for its therapy for the treatment of hemophilia B. The Analyst Chardan's Gbola Amusa maintains a Buy rating on Catalyst Biosciences...

President Donald Trump's administration imposed a 30 percent tariff on all solar equipment made outside of the U.S., a move intended to support domestic solar players, including Sunworks Inc (NASDAQ: SUNW). The Analyst Chardan's James McIlree comments on Sunworks' stock. The Thesis...

Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial.  The Analyst...

Smart glasses manufacturer Vuzix Corp (NASDAQ: VUZI) could have a breakout year in 2018, according to a bullish analyst. Smart glasses are touted as a product of the future but have yet to hit a critical mass with consumers or at the enterprise level. The Analyst James McIlree of Chardan...

Following its meeting with the FDA and the EMA, Uniqure NV (NASDAQ: QURE) announced it would expeditiously advance its adeno-associated virus, or AAV-based gene therapy, AMT-061 into pivotal trials in severe and moderately severe hemophilia B. Reacting to the announcement, Chardan maintains its...

Shares of SAGE Therapeutics Inc (NASDAQ: SAGE) plunged Tuesday after the biopharma company announced its treatment for super-refractory status epilepticus failed its phase III trial. Chardan analyst Gbola Amusa rated the stock a Hold and said a price target was under review. Shares Fall Off A Cliff...

The Medicines Company (NASDAQ: MDCO) announced FDA approval for Vabomere injection to treat adult patients with complicated urinary tract infections. The company said the drug will be made available in the fourth quarter of 2017. Following the announcement, Chardan analyst Gbola Amusa said the...

Two analysts reiterated their Neutral ratings on Novavax, Inc. (NASDAQ: NVAX) after the company announced what it said was positive data for its phase 2 safety and immunogenicity trial of its RSV F vaccine. Novavax was down 24.5 percent and trading at $1.14 at the time of writing, one day after...

Biotech stocks are highly volatile investments, which look toward catalytic events such as FDA decisions, clinical trial results and data presentation at various conferences. Benzinga has compiled a list of some companies scheduled to make presentations at the International Society on Thrombosis...